Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

References for PMC Articles for PubMed (Select 22927417)

1.

CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.

Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J, Pommier Y.

Cancer Res. 2012 Jul 15;72(14):3499-511. doi: 10.1158/0008-5472.CAN-12-1370.

2.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA.

Nature. 2012 Mar 28;483(7391):603-7. doi: 10.1038/nature11003. Erratum in: Nature. 2012 Dec 13;492(7428):290.

3.

Systematic identification of genomic markers of drug sensitivity in cancer cells.

Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O'Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, Baselga J, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, Gray NS, Settleman J, Futreal PA, Haber DA, Stratton MR, Ramaswamy S, McDermott U, Benes CH.

Nature. 2012 Mar 28;483(7391):570-5. doi: 10.1038/nature11005.

4.

Drug discovery: Cell lines battle cancer.

Weinstein JN.

Nature. 2012 Mar 28;483(7391):544-5. doi: 10.1038/483544a. No abstract available.

PMID:
22460893
5.

Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions.

Wagner L.

Sarcoma. 2011;2011:957957. doi: 10.1155/2011/957957. Epub 2011 Apr 6.

6.

Guidelines for the management of soft tissue sarcomas.

Grimer R, Judson I, Peake D, Seddon B.

Sarcoma. 2010;2010:506182. doi: 10.1155/2010/506182. Epub 2010 May 31.

7.

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H.

Blood. 2010 Sep 23;116(12):2040-5. doi: 10.1182/blood-2010-03-276246. Epub 2010 Jun 14.

8.

Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.

Holbeck SL, Collins JM, Doroshow JH.

Mol Cancer Ther. 2010 May;9(5):1451-60. doi: 10.1158/1535-7163.MCT-10-0106. Epub 2010 May 4.

9.

mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities.

Liu H, D'Andrade P, Fulmer-Smentek S, Lorenzi P, Kohn KW, Weinstein JN, Pommier Y, Reinhold WC.

Mol Cancer Ther. 2010 May;9(5):1080-91. doi: 10.1158/1535-7163.MCT-09-0965. Epub 2010 May 4.

10.

Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets.

Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K, Fujiwara H, Kudo Y, Kotera K, Masuzaki H, Tashiro H, Katabuchi H, Inoue I, Tanaka K.

PLoS One. 2010 Mar 12;5(3):e9615. doi: 10.1371/journal.pone.0009615.

11.

Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron.

Reinhold WC, Mergny JL, Liu H, Ryan M, Pfister TD, Kinders R, Parchment R, Doroshow J, Weinstein JN, Pommier Y.

Cancer Res. 2010 Mar 15;70(6):2191-203. doi: 10.1158/0008-5472.CAN-09-3528. Epub 2010 Mar 9.

12.

Evolution of the Schlafen genes, a gene family associated with embryonic lethality, meiotic drive, immune processes and orthopoxvirus virulence.

Bustos O, Naik S, Ayers G, Casola C, Perez-Lamigueiro MA, Chippindale PT, Pritham EJ, de la Casa-Esperón E.

Gene. 2009 Nov 1;447(1):1-11. doi: 10.1016/j.gene.2009.07.006. Epub 2009 Jul 17.

PMID:
19619625
13.

CellMiner: a relational database and query tool for the NCI-60 cancer cell lines.

Shankavaram UT, Varma S, Kane D, Sunshine M, Chary KK, Reinhold WC, Pommier Y, Weinstein JN.

BMC Genomics. 2009 Jun 23;10:277. doi: 10.1186/1471-2164-10-277.

14.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team.

Lancet. 2009 Mar 28;373(9669):1097-104. doi: 10.1016/S0140-6736(09)60500-6. Epub 2009 Mar 18. Erratum in: Lancet. 2009 Aug 8;374(9688):450.

15.

GammaH2AX and cancer.

Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y.

Nat Rev Cancer. 2008 Dec;8(12):957-67. doi: 10.1038/nrc2523. Epub 2008 Nov 13. Review.

16.

Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.

Antony S, Agama KK, Miao ZH, Takagi K, Wright MH, Robles AI, Varticovski L, Nagarajan M, Morrell A, Cushman M, Pommier Y.

Cancer Res. 2007 Nov 1;67(21):10397-405. Erratum in: Cancer Res. 2007 Dec 15;67(24):12034.

17.

The NCI60 human tumour cell line anticancer drug screen.

Shoemaker RH.

Nat Rev Cancer. 2006 Oct;6(10):813-23. Review.

PMID:
16990858
18.

Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel.

Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo WL, Gwadry F, Ajay, Kouros-Mehr H, Fridlyand J, Jain A, Collins C, Nishizuka S, Tonon G, Roschke A, Gehlhaus K, Kirsch I, Scudiero DA, Gray JW, Weinstein JN.

Mol Cancer Ther. 2006 Apr;5(4):853-67.

19.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N.

N Engl J Med. 2005 Oct 20;353(16):1673-84.

20.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team.

N Engl J Med. 2005 Oct 20;353(16):1659-72.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk